Human Derived Cell

Characterization Testing for
Human Cell Banks

Recommended Testing Panel for Human Cell Banks

Robust cell line characterization ensures the safety, quality, and consistency of biopharmaceutical products manufactured using human-derived cell substrates. Compared with rodent cell lines such as CHO, human cell banks require additional considerations related to donor eligibility, human pathogen risk, tissue traceability, and in some cases where tumorigenic potential is deemed to be a risk (e.g. primary cells, stem cells) tumorigenicity and genomic integrity.

A well-defined testing strategy across the cell banking lifecycle—from Master Cell Bank (MCB) to Working Cell Bank (WCB) and End-of-Production Cells (EOP)—is essential to demonstrate cell identity, purity, genetic stability, and freedom from adventitious agents.

Full Assay Name
MCB
WCB
EOP
Test Code
Minimum Sample Requirements
TAT (days)
Safety
Isolator Sterility Testing by Direct Inoculation USP<71> (GMP) – (Up to 100mL TA or 20 Vials)
✅
✅
✅
3000004994
Per USP guidelines
21
Bacteriostasis and Fungistasis (Direct Method) (GMP)1
✅
✅
3000004996
Varies depending on fill/volume
21
EP, JP, and USP Mycoplasma Detection (GMP)
✅
✅
✅
3000005147
1x15mL & 1e6 cells/mL
35
EP, JP, and USP Mycoplasma Detection with Mycoplasmastasis (GMP)
✅
✅
3000007121
1x45mL & 1e6 cells/mL
35
Mycobacterium Tuberculosis DNA Detection by qPCR (GMP)
✅
✅
3000005638
1e7 cells frozen
9
In Vitro Assay for Adventitious Viral Contaminants – (3 Cell Lines) in Plates – Extended Duration (GMP)
✅
✅
✅
3000004805
2x6mL at 1e7 cells/mL
35
AgentSCREEN™ Adventitious Virus Detection in Cell Bank Sample by NGS (GMP)
✅
✅
3000008512
>5e6 cells/mL
28
TEM – Ultrastructural Evaluation of Cell Culture Morphology, with Characterization and Tabulation of Retrovirus-like Particles (GMP)
✅
✅
3000005236
2e7 viable cells
35²
GaLV Detection – Co-Cultivation of Test Article with HEK 293 Cells – 5 passes (GMP)
✅
✅
3000007382
1% or 1e8 cells (whichever is less)
35²
F-PBRT Assay using AMuLV as a Positive Control (GMP)
✅
✅
3000007535
1 mL supernatant
12
Panel for Detection of Human Viral Adventitious Agents by qPCR – Automated (B19, EBV, SV40, CMV, HHV-6, HHV-7, HSV I, HSV II, HHV-8, HCV, HTLV-1, HTLV-2, HAV, HBV, HIV-1 and HIV-2) (GMP)
✅
✅
3000005021
1e7 cells frozen or 7 mL
21
Human Polyomaviruses JCV and BKV DNA Detection by qPCR using TaqMan (GMP)
✅
✅
3000005410
1e7 cells frozen
14
HPV-18 DNA Detection by qPCR using Taqman (GMP)
✅
✅
3000005415
1e7 cells frozen
12
9 CFR Porcine Viruses Detection – 21 day (GMP)3
✅
✅
3000007387
1x500mL serum or 2x8mL cell lysate
31
9 CFR Bovine Viruses Detection in Bovine Serum or Other Products – 21 day (GMP)3
✅
✅
3000007314
1x500mL serum or 2x8mL cell lysate
31
Discriminatory Detection of PCV 1 and PCV 2 by qPCR using TaqMan – Automated (GMP)3
✅
✅
3000005134
1e7 cell pellet or suspension or 1 mL
12
BPyV DNA Detection by qPCR using Taqman (GMP)3
✅
✅
3000005445
1x10e7 cells
12
Identity
Human Cell Line Identification using STR DNA Fingerprinting (GMP)
✅
✅
✅
3000007574
1e6 cells in frozen pellet or frozen cell suspension
10

1 Ingress Study may need to be conducted if the container has not been previously validated.

2 Additional time may be needed if cell bank expansion needs to be performed first.

3 Optional dependent upon risk assessment.

Regulatory Expectations

  • Human cell banks require testing for relevant communicable diseases (e.g., HIV, HBV, HCV), and full traceability from donor to final bank. For human cell-based MCB, WCB, and EOP characterization, regulatory expectations are defined by a broad set of global standards including guidelines from ICH Q5D, Q5A(R2) and Q7, 21 CFR 1271, EMA and WHO.

Requirements for Different Stages of Cell Banking

  • Testing requirements should be risk-based and lifecycle-appropriate. The MCB is the foundational human cell substrate and requires the most extensive testing and comprehensive characterization, including:

    • Cell identity confirmation
    • Purity and sterility
    • Expanded adventitious agent testing, including human-specific viral panels
    • Genetic stability assessment
    • Tumorigenicity testing, where applicable
    • Phenotypic characterization

  • The WCB is derived from the MCB and requires a reduced, confirmatory testing panel to demonstrate derivation from the qualified MCB (identity confirmation), no contamination introduced during expansion, and retention of key phenotypic and functional characteristics. EOP cells represent the maximum population doubling level or passage number used in manufacturing and the purpose of testing these cells is to demonstrate that the cell line remains genetically stable, phenotypically consistent, free from adventitious agents and functionally suitable for production.

cGMP Cell Bank Manufacturing

  • In addition to comprehensive cell bank characterization testing, Minaris also manufactures and characterizes cGMP-compliant cell banks to support both clinical and commercial programs. With more than 20 years of experience in cell bank manufacturing, integrated services include cell expansion, harvest and fill, and cryopreservation using controlled-rate freezers. Banks are delivered fully released, characterized, and ready for use. Minaris provides a dedicated program manager, the same highly trained team from verification run to manufacturing, flexible shift models to support variable expansion and doubling times, and daily readouts and full transparency throughout your program. For human cell substrates, we also support viral safety strategy development, and regulatory-facing data packages tailored to your product classification.

Get in Touch With Our Team Today

Ready to discuss your human-derived cell bank characterization needs? Our team is here to help.

Contact Us